Ovid Therapeutics (OVID) Share-based Compensation (2016 - 2026)

Ovid Therapeutics' Share-based Compensation history runs 11 years deep, the most recent figure standing at $1.0 million for Q1 2026.

• Quarterly Share-based Compensation fell 18.54% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (down 18.29% YoY) and the FY2025 annual result came in at $4.8 million, down 23.41% from the prior year.
• Share-based Compensation was $1.0 million for Q1 2026 at Ovid Therapeutics, down from $1.2 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $12.7 million in Q3 2022 and bottomed at $1.0 million in Q1 2026.
• A 5-year average of $2.2 million and a median of $1.5 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation jumped 997.05% — and 2023, when it plunged 87.2%.
• Ovid Therapeutics' Share-based Compensation stood at $12.7 million in 2022, then slumped by 85.97% to $1.8 million in 2023, then decreased by 29.57% to $1.3 million in 2024, then declined by 5.16% to $1.2 million in 2025, then retreated by 12.47% to $1.0 million in 2026.
• Business Quant data shows OVID's Share-based Compensation at $1.0 million in Q1 2026, $1.2 million in Q4 2025, and $1.1 million in Q3 2025.